Inhibitors of serum/ glucocorticoid‐related kinase 1 (SGK1) protect midbrain dopamine neurons by inhibiting neuroinflammation regulated by the STING pathway while improving pathological synuclein alpha (SNCA) aggregation and behavioral deficits related to PD in in‐vitro and in‐vivo PD models.90 This evidence concerns the gene SNCA and Parkinson disease.